Clinical trials
Recurrent or Metastatic Nasopharyngeal Carcinoma clinical trials
Below are recruiting recurrent or metastatic nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 2,324 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05189054Recruiting
Radiation retreatment for very central chest tumors
This trial tests a focused form of radiation (SBRT) to treat tumors in the very center of the chest that have already been treated with radiation before. It aims to check safety and whether the tumor can be controlled without causing unacceptable side effects.
Beijing, Beijing MunicipalityAges 18–80 - NCT05446545Recruiting
Blood and tissue tests to monitor ovarian cancer using tumor DNA
This study uses a custom lab test on blood (and tumor tissue) to track ovarian cancer returning and to see how well treatment is working. It may help your care team monitor changes over time, especially after certain surgeries.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT06185569Recruiting
French study on outcomes in HR+/HER2- early breast cancer patients with Oncotype DX
This study looks at how well treatments work for people with early-stage, hormone receptor-positive, HER2-negative breast cancer when the Oncotype DX test helps guide therapy. It aims to understand real-world outcomes in French patients.
BesançonAges 18 years+ - NCT05969041RecruitingPhase 1
Early-phase drug trial for advanced epithelial cancers
This Phase 1 study tests a new drug (MT-302) in adults with advanced or metastatic epithelial cancers that have worsened or stopped responding to standard treatment. The goal is to see how the drug works and whether it is safe for people with limited options.
Darlinghurst, New South WalesAges 18 years+ - NCT06229340RecruitingPhase 2
Two drug combinations for advanced cancer with RAS mutations
This trial tests two different treatment combinations (leflunomide alone or with MEK inhibitor and hydroxychloroquine) in people with advanced cancer that has a RAS mutation and has not responded to at least two prior therapies.
Saint PetersburgAges 18–85 - NCT06232122Recruiting
New PET scans to detect ovarian cancer recurrence
This study uses two types of PET/CT scans (68Ga-FAPI-46 and 18F-FDG) to look for any returning ovarian cancer. The goal is to find recurrence early so you and your doctor can plan the next steps.
Taoyuan CityAges 30–80 - NCT05760378RecruitingPhase 3
Famitinib plus immunotherapy for advanced triple-negative breast cancer
This Phase 3 trial tests a combination of famitinib (a cancer drug that targets blood vessel growth) with immunotherapy drugs in people with newly diagnosed advanced triple-negative breast cancer that has spread or cannot be fully removed. It aims to improve how long patients live and how well the cancer responds.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05759546RecruitingPhase 2
Test a PARP and CDK4/6 medicine plus hormone therapy
This Phase 2 study tests whether combining a PARP inhibitor with a CDK4/6 inhibitor and hormone (endocrine) therapy can help people with advanced HR-positive, HER2-negative breast cancer. It’s for certain patients who have not yet had chemotherapy or targeted therapy for metastatic disease.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT05753826RecruitingPhase 2
Study of two medicines for platinum-resistant ovarian cancer
This Phase 2 trial studies whether adding adebrelimab to fuzuloparib can help people with ovarian cancer that comes back quickly after platinum chemotherapy. It is aimed especially at tumors with a specific DNA-repair gene (HRR mutation).
FujianAges 18–70 - NCT03675672RecruitingPhase 4
Preventing repeat bleeding from stomach or upper gut ulcers
This trial studies medicines to help stop bleeding from coming back after you’ve had an “idiopathic” stomach/upper gut ulcer bleed. It may help by reducing ulcer re-bleeding risk in people who don’t have common causes like H. pylori or common ulcer-triggering drugs.
Hong KongAges 18 years+ - NCT05678270RecruitingPhase 2
ICP-192 for FGFR2 fusion bile duct cancer that spread
This Phase 2 trial tests a medicine called ICP-192 in people with intrahepatic bile duct cancer that cannot be removed with surgery and has spread. It is for tumors that have an FGFR2 fusion/rearrangement, especially after prior chemotherapy stopped working.
Hefei, AnhuiAges 18 years+ - NCT04282044RecruitingPhase 1
CRX100 drug trial for advanced cancers with or without pembrolizumab
This Phase 1 trial tests CRX100 (a new cancer medicine) alone and with pembrolizumab (an immune checkpoint drug) in people with advanced solid tumors. It’s mainly designed to check safety and side effects, and to see whether tumors respond, potentially helping people whose cancer has come back or stopped responding to standard treatment.
Scottsdale, ArizonaAges 18 years+ - NCT06230549Recruiting
Adaptive radiotherapy for gynecological tumors
This trial tests a personalized radiation therapy approach for gynecological tumors. It aims to improve treatment by adapting the radiation plan based on changes in the tumor and nearby organs during your therapy course.
Essen, Germany / NRWAges 18 years+ - NCT06247605RecruitingPhase 3
Study of AL8326 for advanced small cell lung cancer
This trial tests a new oral drug called AL8326 for people with advanced small cell lung cancer who have already tried at least two other treatments. The goal is to see if the drug can shrink tumors and help patients live longer.
Changchun, JilinAges 18 years+ - NCT04642027RecruitingPhase 3
PSMA scan-guided salvage radiation after prostate surgery
This trial tests whether using a specialized PSMA PET scan to guide radiation can better treat prostate cancer that returns after prostate surgery. It targets the “prostate bed” area with a shorter, stronger radiation schedule (hypofractionated) to control rising PSA levels.
Arnhem, GelderlandAges 18–80 - NCT07863141RecruitingPhase 2
Maintenance therapy after first-line chemoimmunotherapy for advanced esophageal cancer
This study compares two maintenance treatments after initial chemotherapy plus immunotherapy for advanced esophageal squamous cell carcinoma. The goal is to see if adding anlotinib, a targeted drug that blocks blood vessel growth to tumors, to a PD-1 inhibitor is more effective than the PD-1 inhibitor alone.
Guangzhou, GuangdongAges 18–75 - NCT05638841Recruiting
Study of repeat atrial fibrillation risk after ablation
This study follows adults who have had a procedure to treat an irregular heartbeat, to understand who is more likely to have it return. It may help doctors predict risk and plan follow-up after the procedure.
BeijingAges 18 years+ - NCT05965024Recruiting
Using ctDNA blood tests to predict lung cancer return after surgery
This study checks whether a special blood test (ctDNA) taken before and after surgery can predict whether non-small cell lung cancer will come back. If it works, it may help doctors spot recurrence earlier and guide follow-up care after tumor removal.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04810871Recruiting
Surgery for brain tumors that may come back
This study tests whether removing a brain tumor early, before it shows signs of growing back, can help prevent a recurrence. If you have had treatment before and there is still some tumor left, you may be able to join.
Rochester, MinnesotaAges 18 years+ - NCT07874152Recruiting
Better detection of polyp regrowth after removal
This trial tests advanced imaging techniques during follow-up colonoscopy to better detect if a removed polyp has regrown. It aims to improve how doctors spot potential recurrences at the scar site.
Granada, GranadaAges 18 years+ - NCT04597294RecruitingPhase 3
Preventive pre-op HIPEC for advanced stomach cancer
This Phase 3 trial studies whether adding a heated chemotherapy procedure during surgery (HIPEC) before the main cancer treatment can lower the chance that stomach cancer returns in the belly. It is for people with advanced stomach cancer who are at higher risk of cancer coming back in the peritoneum (the lining of the abdomen).
Krakow, Lesser Poland VoivodshipAges 18–75 - NCT06194734RecruitingPhase 3
KC1036 vs. chemo for advanced esophageal cancer
This study compares a new drug, KC1036, to standard chemotherapy options for people with advanced esophageal squamous cell cancer that has progressed after immunotherapy and at least one chemo. It aims to see if KC1036 works better or has fewer side effects.
BeijingAges 18–75 - NCT06598046RecruitingPhase 2
Utidelone and Capecitabine for triple-negative breast cancer brain metastases
This trial tests a combination of two chemotherapy drugs (Utidelone and Capecitabine) for people with triple-negative breast cancer that has spread to the brain. The goal is to see if the combination can shrink or control the brain tumors.
Zhengzhou, HenanAges 18 years+ - NCT06128837RecruitingPhase 3
Study of a new drug for recurrent small cell lung cancer
This trial tests a drug called LY01610 for people with small cell lung cancer that has returned after initial chemotherapy. It may offer a new treatment option for those whose cancer progressed within 6 months of their last treatment.
BeijingAges 18 years+
Hear when a new Recurrent or Metastatic Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent or metastatic nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 2,324 recruiting recurrent or metastatic nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent or metastatic nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent or metastatic nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Recurrent Nasopharyngeal Carcinoma
- Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
- Metastatic Nasopharyngeal Carcinoma
- Metastatic Nasopharyngeal Squamous Cell Carcinoma
- Recurrent Nasopharyngeal Squamous Cell Carcinoma
- Nasopharyngeal Carcinoma
- Metastatic Renal Cell Carcinoma
- Nasopharyngeal Carcinoma (NPC)
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.